Plus Therapeutics Inc (NASDAQ:PSTV) shares, rose in value on Thursday, July 10, with the stock price down by -0.51% to the previous day’s close as strong demand from buyers drove the stock to $0.35.
Actively observing the price movement in the last trading, the stock closed the session at $0.35, falling within a range of $0.3379 and $0.365. The value of beta (5-year monthly) was 0.624. Referring to stock’s 52-week performance, its high was $2.31, and the low was $0.16. On the whole, PSTV has fluctuated by 0.78% over the past month.
With the market capitalization of Plus Therapeutics Inc currently standing at about $17.90 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-30.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PSTV’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of PSTV currently trading nearly 17.51% and -10.93% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 51.89, while the 7-day volatility ratio is showing 12.04% which for the 30-day chart, stands at 17.67%. Furthermore, Plus Therapeutics Inc (PSTV)’s beta value is 0.64.
A comparison of Plus Therapeutics Inc (PSTV) with its peers suggests the former has fared considerably weaker in the market. PSTV showed an intraday change of -0.51% in last session, and over the past year, it shrunk by -69.48%%.
Data on historical trading for Plus Therapeutics Inc (NASDAQ:PSTV) indicates that the trading volumes over the past 10 days have averaged 36.57 and over the past 3 months, they’ve averaged 26.76 million. According to company’s latest data on outstanding shares, there are 51.00 million shares outstanding.
Nearly 0.29% of Plus Therapeutics Inc’s shares belong to company insiders and institutional investors own 3.14% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.17 million shares as on 2025-06-13, resulting in a short ratio of 0.1. According to the data, the short interest in Plus Therapeutics Inc (PSTV) stood at 357.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 3.49 million. The stock has fallen by -76.60% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PSTV stock heading into the next quarter.
